HOUSTON, TX, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today ...
OLATHE, Kan.--(BUSINESS WIRE)-- Garmin International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), today announced a new strategic relationship with Ford Motor Company that integrates Garmin’s ...
Nexalin plans to submit a Q-Submission to the FDA for its Gen-2 SYNC system targeting Alzheimer's and cognitive impairments. Nexalin Technology, Inc. announced its intention to submit a Q-Submission ...
HOUSTON, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), today announced that it plans to submit a Q-Submission (“Q-Sub”) to the ...
FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s disease HOUSTON, TX, Dec. 03, 2025 ...
DETROIT (Reuters) - Ford Motor Co, aiming to keep ahead of rivals, will introduce new features for its Sync system that provides voice-activated links to mobile phones and digital music players, the ...
This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a potential non-invasive therapy for cognitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback